Response #1--In the past 3 months, list any new information you have heard in regards to cardiovascular outcomes for type 2 diabetes medications?
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Juvoxan approved with superior CVR profile.
improved cardiovascular outcome with Juvoxan
Jar diene and reduction cardiovascular events
no increased heart failure with DPPIV inhibitors
better outcome with certain new medications

Response #2--In the past 3 months, list any new information you have heard in regards to cardiovascular outcomes for type 2 diabetes medications?
Injectables superiority for wt loss and mortality reduction
Intense glycemic control assoc. with increased CV & all-cause mortality
decreased mortality with SGLT-1 inhibitors